News & Blog

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Job Posting: Clinical Operations Manager

Meet the Community: Jamie Cusick

Meet the Community: Aly Bourbeau

December 2025 – Advocacy Newsletter

Meet the Community: Giovanna Boscolo Castilho Gonçalves

FA Community Conversations FA Cardiac Disease Webinar: Recording Available on YouTube

Meet the Community: Renee Brown

Community Statement: 2025 Update from Biogen

CIRM announces $7.4 million funding award for CRISPR/Cas9-mediated gene editing of hematopoietic stem and progenitor cells for Friedreich’s ataxia

Meet the Community: Roxanne

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia